Cell Surface Display Composition for Obesity-Related Muscle Loss

Solution Overview

Problem

Current treatments for obesity do not address muscle loss and atrophy, and existing methods for inhibiting myostatin activity, such as synthetic polypeptides and antibodies, are economically inefficient and pose health risks, while cell surface display technologies lack effective anchoring motifs for stable protein expression.

Innovation Solution

A microorganism transformed with a cell surface display vector expressing myostatin and activin A as a bispecific antigen, utilizing a pgsA gene, is used to treat muscle loss due to obesity, with potential applications in livestock and human health.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If synthetic polypeptides or antibodies are used to inhibit myostatin activity, then muscle growth is promoted, but production cost increases and health risks arise

Engineering Contradiction:

Improvemuscle growth rateVSAvoidproduction cost

Core Design Contradiction:

ProductivityVSEase of manufacture

Solution Approach 1:

The patent uses a bacteriophage display system to produce myostatin inhibitors through bacterial fermentation rather than expensive antibody production. The phage-displayed peptides are produced in large quantities at low cost using standard microbial fermentation techniques, making the therapy economically viable compared to synthetic polypeptides or antibodies

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent employs bacteriophages as intermediaries to deliver myostatin-inhibiting peptides. The phage acts as a vector that displays the inhibitory peptide on its surface, allowing it to bind to myostatin and inhibit its activity. This intermediary approach enables production through bacterial systems rather than requiring complex synthetic biology or antibody manufacturing

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If synthetic polypeptides or antibodies are used to inhibit myostatin activity, then muscle growth is promoted, but safety risks increase

Engineering Contradiction:

Improvemuscle growth rateVSAvoidhealth risks

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent uses a bacteriophage display system to produce myostatin inhibitors through bacterial fermentation rather than expensive antibody production. The phage-displayed peptides are produced in large quantities at low cost using standard microbial fermentation techniques, making the therapy economically viable compared to synthetic polypeptides or antibodies

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent employs bacteriophages as intermediaries to deliver myostatin-inhibiting peptides. The phage acts as a vector that displays the inhibitory peptide on its surface, allowing it to bind to myostatin and inhibit its activity. This intermediary approach enables production through bacterial systems rather than requiring complex synthetic biology or antibody manufacturing

Inventive Principle:

Principle #24Intermediary (Mediator)

3Stability of the object's composition

If cell surface display technology is used without effective anchoring motifs, then protein expression is unstable, but developing suitable anchoring motifs increases device complexity

Engineering Contradiction:

Improveprotein expression stabilityVSAvoidanchoring motif complexity

Core Design Contradiction:

Stability of the object's compositionVSDevice complexity

Solution Approach 1:

The patent utilizes the pgsA gene product as a universal anchoring motif that can stably display various myostatin-inhibiting peptides on the bacteriophage surface. This single anchoring system serves multiple functions: it provides stable cell surface display, maintains peptide activity, and enables scalable production without requiring different anchoring mechanisms for different peptide variants

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent employs bacteriophages as intermediaries to deliver myostatin-inhibiting peptides. The phage acts as a vector that displays the inhibitory peptide on its surface, allowing it to bind to myostatin and inhibit its activity. This intermediary approach enables production through bacterial systems rather than requiring complex synthetic biology or antibody manufacturing

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250387440A1Pharmaceutical Composition for Treatment of Muscle Loss Due to Obesity Treatment

Publication Date: 2025.12.25 NORTHSTRIVE BIOSCIENCES INC

AI summary

The present invention relates to a pharmaceutical composition including a microorganism transformed with a cell surface display vector operably linked with a gene encoding myostatin and activin A proteins for the treatment of muscle loss related to obesity. The pharmaceutical composition may include pharmaceutically viable excipients, such as antiadherents, binders, carriers, coatings, colorants, disintegrants, diluents, flavorings, glidants, lubricants, preservatives, sorbents, or vehicles.